Menu

Evaluating New 3-D Systems for Disease Modeling, Drug Discovery, and Toxicology

Bio-Techne invites you to join them for an educational webinar.

Feb 13, 2018
The Scientist Creative Services Team

Evaluating New 3-D Systems for Disease Modeling, Drug Discovery, and Toxicology from thescientistllc on Vimeo.

Cell and tissue-based models are a necessary step in the workflow for toxicology testing, drug discovery, and disease modeling. In recent years, the research and pharmaceutical industries have adopted more-complex ex vivo and in vitro 3-D tissue models because of their better predictive power. In this webinar, representatives from Bio-Techne will discuss the history of cell- and tissue-based model systems for toxicology, drug screening, and disease modeling. They also introduce MimEX™ Tissue Model Systems, a transformative culturing platform that builds upon the physiological and structural advancements of current organoid models by producing 3-D tissue with better accessibility and lower variability. Tune in to learn more about MimEX 3-D Tissue.

Topics to be covered:

  • History of cell and tissue model systems for toxicology and disease modeling
  • Troubleshooting variability in iPSC-based models
  • Advantages and disadvantages of current 3-D culture systems

Meet the Speakers:

Scott Schachtele, PhD
Product Manager, Stem Cells and Cell Culture
Bio-Techne

 

 

Kevin Flynn, PhD
Scientist, Stem Cell Research and Development
Bio-Techne

 

 

Webinar Sponsored By:

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.